Second-generation inhibitors of Bruton tyrosine kinase
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib. Resistance to ibrutinib was also reported. The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib. This review summarizes the clinical development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111.
KeywordsChronic Lymphocytic Leukemia Maximal Tolerate Dose Mantle Cell Lymphoma Overall Response Rate Chronic Lymphocytic Leukemia Patient
Bruton tyrosine kinase
overall response rate
maximal tolerated dose
Bruton tyrosine kinase
Bruton tyrosine kinase (BTK) was initially implicated in the pathogenesis of X-linked agammaglobulinemia [1, 2, 3, 4]. The gene encoding the BTK molecule was isolated in 1993 and was named independently at the time as B cell progenitor kinase and agammaglobulinemia tyrosine kinase [5, 6]. The BTK gene is located on the X chromosome in the region Xq21.3-22.1. The gene contains 19 exons and the open reading frame has 1977 nucleotides. BTK is a 76-kDa polypeptide with 659 amino acid residues.
Ibrutinib: the first-generation BTK inhibitor
Targeting novel biomarkers that are driver molecules regulating cancer cell growth and differentiation has revolutionized drug development for cancer therapy [18, 19, 20, 21, 22, 23, 24]. Novel agents targeting biomarker molecules in lymphocytes are revolutionizing treatment of lymphoid malignancies [25, 26, 27, 28, 29, 30, 31, 32, 33]. Since BTK is a critical effector molecule for B cell development and plays a major role in lymphomagenesis, BTK inhibitors have been investigated as potential treatments [11, 34, 35, 36, 37]. To date, ibrutinib remains the only BTK inhibitor approved for several lymphoproliferative malignancies [38, 39, 40].
Ibrutinib is the first-in-class, highly potent small molecule inhibitor that selectively binds to cysteine 481 residue in the allosteric inhibitory segment of BTK kinase domain. The compound irreversibly abrogates the full activation of BTK by inhibiting its autophosphorylation at tyrosine residue 223 . Ibrutinib (imbruvica) has been approved for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenstrom’s macroglobulinemia [11, 35, 36, 38, 39, 40, 42, 43, 44, 45, 46]. However, untoward effects, such as bleeding, rash, diarrhea and atrial fibrillation have been observed and attributed in part to its off-target effects on the epidermal growth factor receptor and the Tec family proteins other than BTK [8, 43, 44, 47, 48, 49, 50, 51, 52, 53]. In addition, resistance to ibrutinib has been observed [54, 55]. As a result, second-generation BTK inhibitors are being developed.
Resistance mechanisms for ibrutinib
The estimated progression-free survival (PFS) rate among relapsed/refractory CLL patients treated with ibrutinib was reported to be 75 % at 26 months . The mechanisms of acquired resistance to ibrutinib are under active investigation [54, 55, 56].
In one case report, a CLL patient developed resistance after 21 months on ibrutinib at a dose as high as 840 mg daily . Through sequencing RNA from pre- and post-treatment samples, a thymidine-to-adenine mutation at nucleotide 1634 of the BTK complementary DNA (cDNA) was discovered. This led to a substitution of serine for cysteine at residue 481 (C481S) (Fig. 1). Ibrutinib forms a covalent bond with the sulfhydryl group of C481 of BTK and irreversibly inhibits the kinase activity of BTK . The new amino acid residue S481 prevents ibrutinib from covalently binding to the BTK mutants, converting irreversible inhibition of the BTK to reversible inhibition. When the phosphorylation at tyrosine residue 223 was studied, the IC50 (half-maximal inhibitory concentration) of ibrutinib changed to 1006 nM on C481S mutant BTK from 2.2 nM on non-mutant BTK . The C481S mutation was below the detectable level in ibrutinib-naïve patients, suggesting that this mutant clone was selected out through BTK inhibition by ibrutinib . The same C481S BTK mutation was also found to be responsible for acquired resistance to ibrutinib in MCL [56, 58].
In addition to the C481S mutation, three distinct mutations in PLCγ2 were found in two CLL patients who became resistant to ibrutinib . Two mutations in PLCγ2, R665W and L845F, could lead to a gain-of-function. Since PLCγ2 lies immediately downstream of BTK, these mutants could therefore bypass the inactive BTK and allow autonomous B cell receptor activity despite the inactive BTK. In an update, two of six patients with Richter transformation after ibrutinib therapy had the BTK C481S mutation, while 100 % patients (10/10) with progression but no Richter transformation had either one or both BTK C481S and PLCγ2 mutations . None of the mutations were present in any of the patients with prolonged lymphocytosis on ibrutinib therapy.
Approximately 32 % of MCL patients had primary resistance to ibrutinib since the response rate of MCL to ibrutinib was 68 % . This suggests that additional mechanisms of resistance exist. It was demonstrated that inhibition of ERK1/2 and AKT correlated with cellular response to BTK inhibition in vitro and in primary tumor samples . Taken together, primary ibrutinib resistance in MCL is not mainly caused by ineffective ibrutinib inhibition of BTK but rather involves PI3K-AKT activation. In addition, transcriptome sequencing displayed recurrent mutations in TRAF2 or BIRC3 in 15 % of the 165 patient samples . These genetic lesions in the alternative NF-kB pathway exposed another mechanism of primary ibrutinib resistance in MCL.
In patients with Waldenstrom’s macroglobulinemia (WM), MYD88 and CXCR4 mutations have been shown to be associated with clinical response to ibrutinib [46, 60, 61]. The effect of MYD88 and CXCR4 mutations on outcomes of ibrutinib in 63 patients with WM was reported [39, 46]. Results indicate that patients with MYD88L265PCXCR4WT have the highest response rate (100 % overall response rate). BCL2 can protect against ibrutinib triggered apoptosis regardless of CXCR4WHIM mutation status [60, 62], supporting the use of BCL2 inhibitor in refractory B cell malignancies .
There is, however, no relationship between MYD88 mutation status and ibrutinib response in patients with diffuse large B cell lymphoma (DLBCL), particularly the ABC subtype. Instead, mutations that affect the signaling of B cell and T cell receptors, such as CD79A/B and CARD11 may be responsible for lower response to ibrutinib [39, 63, 64].
Second-generation BTK inhibitors
The emerging resistance to and off-target side effects of ibrutinib have led to active development of second-generation and more specific BTK inhibitors, such as ACP-196, ONO/GS-4059, and BGB-3111.
ACP-196, also known as acalabrutinib, is a novel irreversible second-generation BTK inhibitor [34, 37]. It is more potent and selective than ibrutinib with reduced off-target side effects. As shown through IC50 determinations on nine kinases with a cysteine residue in the same position as BTK, ACP-196 had virtually no inhibition on kinase activities of EGFR, ITK, TEC, etc. [37, 65, 66].
A phase 1/2, multicenter, open-label, and dose-escalation clinical trial on ACP-196 (NCT02029443) has been underway in relapsed and refractory CLL patients. In the last update, 61 patients with relapsed CLL were enrolled . In the phase 1 portion of this study, patients were treated with ACP-196 at an increasing dose of 100 to 400 mg once daily, while in the phase 2 expansion portion, 100 mg twice daily was given. The median follow-up time was 14.3 months (range 0.5–20), the overall response rate (ORR) was 95 %, with 85 % partial response (PR), 10 % PR, and 5 % SD (stable disease). Among them, patients with chromosome 17p13.1 deletion had 100 % ORR. The most common adverse events were headache, diarrhea, and weight gain, without dose-limiting toxicities, and no cases of atrial fibrillation and Richter’s transformation.
Currently, a phase 3 study (NCT02477696) directly comparing ACP-196 with ibrutinib in high-risk patients with relapsed CLL has commenced. In addition, multiple trials of ACP-196 on other hematological malignancies and solid tumors are underway .
ONO/GS-4059 is another highly potent and more specific BTK inhibitor. Its anti-tumor activities were studied in preclinical models  and in the clinical trials for the treatment of B cell malignancies [68, 69, 70, 71, 72, 73].
In an ABC-DLBCL cell line (TMD-8) xenograft model, the effects of ONO/GS-4059 on gene transcription in vivo were analyzed . The results indicated that ONO/GS-4059 affects a core set of genes that contain nine down-regulated and eight up-regulated genes in a dose-dependent manner. Among these, CXCL-10 is the most down-regulated gene by ONO/GS-4059 and is involved in the pathological processes of human disorders, such as infectious diseases and inflammatory and autoimmune diseases as well as cancer. This study confirmed the profound anti-proliferative activity of ONO/GS-4059 by inhibiting BTK in the TMD-8 model.
The first-in-human phase I study of ONO/GS-4059 was on relapsed/refractory B cell malignancies (NCT01659255) . The efficacy and safety data on 90 evaluable patients (CLL n = 28, MCL n = 16, DLBCL n = 35, FL n = 5, WM n = 3, MZL n = 2, and SLL n = 1) were reported [68, 69, 70, 72]. The dose-escalating 3 + 3 cohorts ranged from 20 mg to 600 mg once daily, and twice-daily regimens had doses of 240 mg and 300 mg. In the CLL group, 96 % (24/25) of patients had objective responses within the first 3 months of therapy. Rapid responses in the lymph nodes were noted with concurrent lymphocytosis . In the MCL group, 92 % (11/12) of patients responded to ONO/GS-4059 (six PR and five complete responses (CRs)/Cru). In non-germinal center DLBCL, 35 % (11/31) of patients responded with 2 confirmed CR, 1 CRu, and 8 PR. In contrast to CLL and MCL, responses of DLBCL were much less durable. Notably, CLL and MCL patients with a chromosome 17p deletion and/or TP53 mutation as well as those following allogeneic stem cell transplantation responded rapidly. The pharmacokinetics of ONO/GS-4059 showed rapid absorption and elimination with a half-life of 6.5 to 8 h. The BTK occupancy in the peripheral blood was maintained for at least 24 h across all dose levels. Most importantly, ONO/GS-4059 was found to be well tolerated in all groups. There was no maximal tolerated dose (MTD) reached in the CLL group. In the lymphoma cohort, 480 mg once daily was the MTD. Drug-related hematoma was reported in one patient. Atrial fibrillation was observed, but it was reported to be not drug-related . In the kinomescan study, ONO/GS-4059 was found to have significantly weaker activity on TEC kinase . Therefore, ONO/GS-4059 has a favorable safety profile along with preliminary efficacy in patients with relapsed/refractory B cell malignancies.
Further investigations of ONO/GS-4059 are ongoing to ascertain its advantages in combination therapies. Combination of idelalisib and ONO/GS-4059 synergistically inhibited the growth of a subset of DLBCL and MCL cell lines . This combination led to more significant growth inhibition of the A20 mutant TMD8 cells than single agent idelalisib. This suggested that the combination therapy may overcome some mechanisms of resistance in the BTK signaling pathway. In addition, Jones et al. investigated the potential activity of combinations of the B cell receptor pathway inhibitors, entospletinib, ONO/GS-4059, and idelalisib, with the BCL2 inhibitor ABT-199 in primary CLL cells [73, 74, 75, 76]. Results showed that their combination synergistically increased the apoptosis in these primary CLL cells and achieved the maximal levels of apoptosis. These data support clinical investigation of these combinations in patients with CLL.
In preclinical studies, BGB-3111 showed more restricted off-target activities against a panel of kinases, including ITK. Due to the weaker activity on ITK, BGB-3111 was at least 10 times weaker than ibrutinib in inhibiting rituximab-induced ADCC activity. Both in the REC-1 MCL and ABC subtype DLBCL (TMD-8) xenograft models, BGB-3111 induced dose-dependent anti-tumor effects and demonstrated superior efficacy in comparison with ibrutinib. Toxicity study in rats indicated that BGB-3111 was very well tolerated, and the MTD was not reached when it was dosed up to 250 mg/kg/day . These preclinical data showed that BGB-3111 is a highly selective and potent BTK inhibitor.
The first-in-human, open-label phase 1 trial of BGB-3111 is ongoing as a modified 3 + 3 dose-escalation design (40, 80, 160, 320 mg PO QD; 160 mg PO BID) in patients with advanced B cell malignancies . The pharmacokinetics, efficacy and safety of BGB-3111 were assessed in this study. At the last update from the 2015 ASH annual meeting, 25 patients were enrolled in five cohorts: 40 mg (n = 4), 80 mg (n = 5), 160 mg (n = 6), 320 mg (n = 6) QD, and 160 mg BID (n = 4). Sixty-four percent (16/25) of patients had objective responses, including 1 CR and 6 SD. There were no drug-related adverse events (AEs), no dose-limited toxicities (DLT) reported yet, and the MTD was not reached. The preliminary phase 1 results suggested that the selective BTK inhibitor BGB-3111 is clinically active and tolerable. However, the study report was preliminary, and its toxicity profile and clinical efficacy remain to be determined.
Comparison of ibrutinib with second- generation BTK inhibitors
EGFR, ITK, TEC
Activity on C481S
Jingjing Wu is a recipient of the Henan Provincial Grant for Overseas Research for Young Leaders of Medical Technology (No. 2014041). She also received grant support from the Natural Science Foundation of China (NSFC No. 81201793). The grants supported her research training at the Division of Hematology and Oncology, New York Medical College and Westchester Medical Center, Valhalla, NY, USA.
Availability of data and materials
The material supporting the conclusion of this review has been included within the article.
DL designed the study. JW and DL drafted the manuscript. CL and ST participated in the manuscript preparation and revisions. ST and DL designed and finalized the figure. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
This is not applicable for this review.
Ethics approval and consent to participate
This is not applicable for this review.
- 7.Smith CI, Baskin B, Humire-Greiff P, Zhou JN, Olsson PG, Maniar HS, Kjellen P, Lambris JD, Christensson B, Hammarstrom L, et al. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol. 1994;152(2):557–65.PubMedGoogle Scholar
- 21.Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10.PubMedCrossRefGoogle Scholar
- 24.Tam C, Grigg AP, Opat S, Ku M, Gilbertson M, Anderson MA, Seymour JF, Ritchie DS, Dicorleto C, Dimovski B, Hedrick E, Yang J, Wang L, Luo L, Xue L, Roberts AW. The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. Blood. 2015;126(23):832.Google Scholar
- 30.Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, Topp M, Little M, Zhukovsky EA. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. mAbs. 2015;7(3):584–604.PubMedPubMedCentralCrossRefGoogle Scholar
- 36.Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94.PubMedCrossRefGoogle Scholar
- 37.Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–32.PubMedCrossRefGoogle Scholar
- 38.Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O’Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.PubMedPubMedCentralCrossRefGoogle Scholar
- 40.Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.PubMedPubMedCentralCrossRefGoogle Scholar
- 41.Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075–80.PubMedPubMedCentralCrossRefGoogle Scholar
- 43.Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O’Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37.PubMedPubMedCentralCrossRefGoogle Scholar
- 44.Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.PubMedPubMedCentralCrossRefGoogle Scholar
- 46.Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–40.PubMedCrossRefGoogle Scholar
- 47.Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O’Brien S. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–506.PubMedPubMedCentralCrossRefGoogle Scholar
- 54.Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–94.PubMedPubMedCentralCrossRefGoogle Scholar
- 56.Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S, Johnson A, Chang B, Ely S, Elemento O, Mason CE, Leonard JP, Chen-Kiang S. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4(9):1022–35.PubMedPubMedCentralCrossRefGoogle Scholar
- 59.Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dorken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, Lenz G, Stegmeier F. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20(1):87–92.PubMedCrossRefGoogle Scholar
- 60.Cao Y, Hunter ZR, Liu X, Xu L, Yang G, Chen J, Patterson CJ, Tsakmaklis N, Kanan S, Rodig S, Castillo JJ, Treon SP. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s macroglobulinemia. Leukemia. 2015;29(1):169–76.PubMedCrossRefGoogle Scholar
- 62.Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, Tsakmaklis N, Hatjiharissi E, Kanan S, Davids MS, Castillo JJ, Treon SP. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015;170(1):134–8.PubMedCrossRefGoogle Scholar
- 63.Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92.PubMedPubMedCentralCrossRefGoogle Scholar
- 64.Yang Y, Shaffer 3rd AL, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Balasubramanian S, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, Waldmann TA, Staudt LM. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6):723–37.PubMedPubMedCentralCrossRefGoogle Scholar
- 65.Covey T, Barf T, Gulrajani M, Krantz F, van Lith B, Bibikova E, van de Kar B, de Zwart E, Hamdy A, Izumi R, Kaptein A. Abstract 2596: ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Res. 2015;75(15 Supplement):2596.CrossRefGoogle Scholar
- 66.Harrington BK, Gulrajani M, Covey T, Kaptein A, Van Lith B, Izumi R, Hamdy A, Ulrich RG, Byrd JC, Lannutti BJ, Johnson AJ. ACP-196 is a second generation inhibitor of bruton tyrosine kinase (BTK) with enhanced target specificity. Blood. 2015;126(23):2908.Google Scholar
- 67.Yasuhiro T, Yoshizawa T, Hotta S, Ariza Y, Ueda Y, Kozaki R, Birkett J. Abstract 2452: ONO-4059, a novel oral Bruton’s tyrosine kinase (Btk) inhibitor that demonstrates potent pharmacodynamic activity through Phosphorylated Btk (P-Btk) inhibition, in addition to effective anti-tumour activity in a TMD-8 (DLBCL) xenograft model. Cancer Res. 2013;73(8 Supplement):2452.CrossRefGoogle Scholar
- 68.Dyer M HC, Rule S, et al.: Abstract 8553: the Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: single-agent activity in patients with relapsed and refractory non-GCB-DLBCL. J Clin Oncol 2014, 32:suppl; abstr 8553.Google Scholar
- 69.Rule S SN, Salles G, et al.. Abstract 4397: a phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed/refractory B-cell lymphoma. Blood. 2013;122(21):Abstract #4397.Google Scholar
- 70.Salles G KL, Rule S, et al.: Abstract 676: a phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed/refractory and high risk chronic lymphocytic leukaemia (CLL). Blood. 2013;122(21):Abstract #676.Google Scholar
- 71.Tannheimer S, Liu J, Sorensen R, Yahiaoui A, Meadows S, Li L, Yue P, Keegan KS, Bates J, Tumas D, Queva C. Combination of idelalisib and ONO/GS-4059 in lymphoma cell lines sensitive and resistant to BTK inhibitors. Blood. 2015;126(23):3697.Google Scholar
- 72.Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411–9.PubMedPubMedCentralCrossRefGoogle Scholar
- 73.Jones R, Axelrod MJ, Tumas D, Quéva C, Di Paolo J. Combination effects of B cell receptor pathway inhibitors (entospletinib, ONO/GS-4059, and idelalisib) and a BCL-2 inhibitor in primary CLL cells. Blood. 2015;126(23):1749.Google Scholar
- 74.Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22.PubMedCrossRefGoogle Scholar
- 75.Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8.PubMedCrossRefGoogle Scholar
- 78.Fraser G, Cramer P, Demirkan F, Santucci Silva R, Pylypenko H, Grosicki S, Janssens A, Pristupa A, Mayer J, Dilhuydy M-S, Loscertales J, Goy A, Avigdor A, Rule S, Phelps C, Mahler M, Salman M, Howes AJ, Balasubramanian S, Chanan-Khan AAA. Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. ASCO Meet Abstr. 2016;34(15_suppl):7525.Google Scholar
- 79.Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15(9):1019–26.PubMedCrossRefGoogle Scholar
- 80.Topp MS, Gokbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foa R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Bruggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2014;16(1):57–66.PubMedCrossRefGoogle Scholar
- 81.Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, Neumann SA, Horst HA, Raff T, Viardot A, Stelljes M, Schaich M, Kohne-Volland R, Bruggemann M, Ottmann OG, Burmeister T, Baeuerle PA, Nagorsen D, Schmidt M, Einsele H, Riethmuller G, Kneba M, Hoelzer D, Kufer P, Bargou RC. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185–7.PubMedCrossRefGoogle Scholar
- 83.Linder K, Gandhiraj D, Hanmantgad M, Seiter K, Liu D. Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG. Exp Hematol Oncol. 2016;5:20.PubMedPubMedCentralCrossRefGoogle Scholar
- 85.Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24.PubMedPubMedCentralCrossRefGoogle Scholar
- 86.Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.PubMedCentralPubMedCrossRefGoogle Scholar
- 88.Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, Negri GL, Lin Y, Zou J, Mallon BS, Maude S, Teachey DT, Barrett DM, Orentas RJ, Daugaard M, Sorensen PH, Grupp SA, Fry TJ. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood. 2015;126(5):629–39.PubMedPubMedCentralCrossRefGoogle Scholar
- 89.Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.PubMedPubMedCentralCrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.